trending Market Intelligence /marketintelligence/en/news-insights/trending/gxlddihnv1tnsdatxhtkcg2 content esgSubNav
In This List

Lixte Biotechnology names 2 directors

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Lixte Biotechnology names 2 directors

Lixte Biotechnology Holdings Inc. appointed Yun Yen and Winson Ho to its board.

Yen is president emeritus of Taipei Medical University and chair professor of the doctorate program for cancer biology and drug discovery.

Ho is a pediatric neurosurgery fellow at the University of Utah School of Medicine. He previously served as a research fellow at a division of the National Institutes of Health, and conducted research on Lixte's lead clinical compound.

New York-based Lixte Biotechnology develops treatments for cancer and nonmalignant diseases.